[go: up one dir, main page]

MA40111B1 - Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 - Google Patents

Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1

Info

Publication number
MA40111B1
MA40111B1 MA40111A MA40111A MA40111B1 MA 40111 B1 MA40111 B1 MA 40111B1 MA 40111 A MA40111 A MA 40111A MA 40111 A MA40111 A MA 40111A MA 40111 B1 MA40111 B1 MA 40111B1
Authority
MA
Morocco
Prior art keywords
protein
tetrahydronaphthalene
derivatives
compounds
inhibiting mcl
Prior art date
Application number
MA40111A
Other languages
English (en)
Other versions
MA40111A1 (fr
Inventor
Sean P Brown
Yunxiao Li
Mike Elias Lizarzaburu
Brian S Lucas
Nick A Paras
Joshua Taygerly
Marc Vimolratana
Xianghong Wang
Ming Yu
Manuel Zancanella
Liusheng Zhu
Buenrostro Ana Gonzalez
Zhihong Li
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA40111A1 publication Critical patent/MA40111A1/fr
Publication of MA40111B1 publication Critical patent/MA40111B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/11—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/56—Unsaturated compounds containing hydroxy or O-metal groups containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des inhibiteurs de la protéine de la leucémie myéloïde 1 (mcl-1), leurs procédés de préparation, des compositions pharmaceutiques associées, et leurs méthodes d'utilisation. L'invention concerne, par exemple, de composés de formule (i) et des sels pharmaceutiquement acceptables de ceux-ci, ainsi que des compositions comprenant ces composés. Les composés et les compositions de l'invention peuvent être utilisés, par exemple, dans le traitement de maladies ou affections telles que le cancer.
MA40111A 2014-08-29 2015-08-28 Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 MA40111B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462043929P 2014-08-29 2014-08-29
PCT/US2015/047472 WO2016033486A1 (fr) 2014-08-29 2015-08-28 Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1

Publications (2)

Publication Number Publication Date
MA40111A1 MA40111A1 (fr) 2018-06-29
MA40111B1 true MA40111B1 (fr) 2018-12-31

Family

ID=54238507

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40111A MA40111B1 (fr) 2014-08-29 2015-08-28 Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1

Country Status (41)

Country Link
US (7) US9562061B2 (fr)
EP (2) EP3186259B1 (fr)
JP (1) JP6502479B2 (fr)
KR (1) KR102466351B1 (fr)
CN (1) CN107001387B (fr)
AP (1) AP2017009827A0 (fr)
AR (1) AR101729A1 (fr)
AU (1) AU2015308735B2 (fr)
BR (1) BR112017004209B1 (fr)
CA (1) CA2959615C (fr)
CL (1) CL2017000469A1 (fr)
CO (1) CO2017002998A2 (fr)
CR (1) CR20170116A (fr)
CY (1) CY1121195T1 (fr)
DK (1) DK3186259T3 (fr)
EA (1) EA031223B1 (fr)
ES (2) ES2706309T3 (fr)
HR (1) HRP20190053T1 (fr)
HU (1) HUE041806T2 (fr)
IL (2) IL250843B (fr)
JO (1) JO3474B1 (fr)
LT (1) LT3186259T (fr)
MA (1) MA40111B1 (fr)
ME (1) ME03313B (fr)
MX (1) MX379155B (fr)
MY (1) MY176235A (fr)
PE (1) PE20170892A1 (fr)
PH (1) PH12017500367B1 (fr)
PL (1) PL3186259T3 (fr)
PT (1) PT3186259T (fr)
RS (1) RS58276B1 (fr)
SG (1) SG11201701525WA (fr)
SI (1) SI3186259T1 (fr)
SM (1) SMT201900048T1 (fr)
TN (1) TN2017000067A1 (fr)
TR (1) TR201901312T4 (fr)
TW (1) TWI676628B (fr)
UA (1) UA118233C2 (fr)
UY (1) UY36285A (fr)
WO (1) WO2016033486A1 (fr)
ZA (2) ZA201701763B (fr)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3474B1 (ar) 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
US11306107B2 (en) 2016-02-25 2022-04-19 Amgen Inc. Compounds that inhibit MCL-1 protein
WO2017197036A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères spirocycliques pour la dégradation de protéines cibles
EP3455219A4 (fr) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. Dégronimères de c3-glutarimide liés à une amine pour la dégradation de protéines cibles
EP3455218A4 (fr) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. Dégronimères de type glutarimide liés au carbone c3 pour la dégradation de protéines cibles
EP4491236A3 (fr) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Dégronimères hétérocycliques pour la dégradation de protéines cibles
AU2017300738A1 (en) 2016-07-22 2019-02-07 Les Laboratoires Servier Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
JP6453507B2 (ja) 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Ｍｃｌ−１タンパク質を阻害する化合物
CN118440096A (zh) 2017-06-20 2024-08-06 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
AU2018318692A1 (en) * 2017-08-15 2020-03-12 AbbVie Deutschland GmbH & Co. KG Macrocyclic MCL-1 inhibitors and methods of use
SG10202106345VA (en) * 2017-08-15 2021-07-29 Abbvie Inc Macrocyclic mcl-1 inhibitors and methods of use
EP3668878B1 (fr) * 2017-08-18 2025-05-21 Amgen Inc. Composés inhibant la protéine mcl-1
US11279712B2 (en) 2017-08-29 2022-03-22 Amgen Inc. Macrocyclic compounds that inhibit MCL-1 protein
MA54985A (fr) 2018-03-05 2021-12-29 Amgen Inc Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1
KR102732008B1 (ko) * 2018-05-14 2024-11-20 길리애드 사이언시즈, 인코포레이티드 Mcl-1 억제제
JP2022506973A (ja) * 2018-11-09 2022-01-17 プレリュード セラピューティクス，インコーポレイティド 骨髄性細胞白血病－１（ｍｃｌ－１）タンパク質の阻害剤としてのスピロ－スルホンアミド誘導体
CN120698985A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
WO2020147802A1 (fr) * 2019-01-18 2020-07-23 Ascentage Pharma (Suzhou) Co., Ltd. Spiroéthers macrocycliques utilisés en tant qu'inhibiteurs de mcl-1
UY38700A (es) 2019-05-20 2020-12-31 Novartis Ag Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
JP7617861B2 (ja) * 2019-06-21 2025-01-20 ヤンセン ファーマシューティカ エヌ．ベー． Ｍｃｌ－１の大環状阻害剤
PE20220231A1 (es) 2019-06-25 2022-02-07 Gilead Sciences Inc Proteinas de fusion flt3l-fc y metodos de uso
ES2987630T3 (es) 2019-07-09 2024-11-15 Janssen Pharmaceutica Nv Derivados de espirociclos macrocíclicos como inhibidores de MCL-1
EP3771469A1 (fr) * 2019-07-30 2021-02-03 Amgen, Inc Formulations et dosages pour l'administration d'un composé inhibant la protéine mcl1
WO2021047616A1 (fr) * 2019-09-12 2021-03-18 苏州亚盛药业有限公司 Composé spiro à base d'heptane hétérocyclique d'oxynitrure, intermédiaire et procédé de préparation associé
US11795223B2 (en) 2019-10-18 2023-10-24 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
MX2022005123A (es) 2019-10-31 2022-05-30 Forty Seven Inc Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico.
AU2020379731A1 (en) * 2019-11-04 2022-05-05 Revolution Medicines, Inc. Ras inhibitors
CA3159561A1 (fr) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Inhibiteurs de ras
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
US11325891B2 (en) * 2019-11-26 2022-05-10 Gilead Sciences, Inc. Processes and intermediates for preparing MCL1 inhibitors
MX2022007930A (es) 2019-12-24 2022-08-08 Carna Biosciences Inc Compuestos moduladores de diacilglicerol quinasa.
BR112022014623A2 (pt) 2020-02-14 2022-09-13 Jounce Therapeutics Inc Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
EP4107161A1 (fr) * 2020-02-21 2022-12-28 Janssen Pharmaceutica NV Dérivés d'indole macrocycliques en tant qu'inhibiteurs de mcl-1
JP2021161114A (ja) * 2020-03-31 2021-10-11 アムジエン・インコーポレーテツド Ｍｃｌ−１化合物のメチル化
US20230212191A1 (en) * 2020-04-16 2023-07-06 Prelude Therapeutics, Incorporated Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
US20240043427A1 (en) 2020-05-01 2024-02-08 Gilead Sciences, Inc. Cd73 compounds
CA3181214A1 (fr) * 2020-05-06 2021-11-11 Amgen Inc. Synthese d'intermediaires alcooliques proteges vinyliques
MX2022013961A (es) 2020-05-06 2022-11-30 Amgen Inc Sintesis de productos intermedios de sulfonamida.
TWI827924B (zh) * 2020-05-06 2024-01-01 美商安進公司 大環Mcl-1抑制劑中間體的閉環合成
JP7752635B2 (ja) * 2020-05-06 2025-10-10 アムジエン・インコーポレーテツド ビニルアルコール中間体の合成
TWI867217B (zh) * 2020-05-06 2024-12-21 美商安進公司 乙烯基環丁基中間體之合成
US20230219906A1 (en) 2020-06-10 2023-07-13 Janssen Pharmaceutica Nv Macrocyclic-2-amino-3-fluoro-but-3-enamides as inhibitors of mcl-1
IL300977A (en) 2020-09-03 2023-04-01 Amgen Inc Removal of diol symmetry via nucleophilic aromatic substitution
PE20231207A1 (es) 2020-09-15 2023-08-17 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer
CN116457334A (zh) * 2020-11-19 2023-07-18 吉利德科学公司 用于制备大环mcl1抑制剂的方法和中间体
US20240042051A1 (en) 2020-11-24 2024-02-08 Francesca Rocchetti Mcl-1 inhibitor antibody-drug conjugates and methods of use
MX2023006144A (es) * 2020-11-25 2023-06-06 Amgen Inc Alquenilacion enantioselectiva de aldehidos.
EP4008324A1 (fr) 2020-12-07 2022-06-08 Cellestia Biotech AG Combinaisons comprenant un inhibiteur d'une protéine anti-apoptotique, telle que bcl-2, bcl-xl, bclw ou mcl-1, et un inhibiteur de voie de signalisation notch pour le traitement du cancer
EP4255409A1 (fr) 2020-12-07 2023-10-11 Cellestia Biotech AG Combinaisons pharmaceutiques pour le traitement du cancer
ES3026771T3 (en) 2020-12-17 2025-06-12 Janssen Pharmaceutica Nv Macrocyclic branched 3-fluoro-but-3-enamides as inhibitors of mcl-1
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
AU2022267722A1 (en) 2021-04-26 2023-12-14 Janssen Pharmaceutica Nv Macrocyclic 2-allyltetrahydrofurans as inhibitors of mcl-1
PE20240089A1 (es) 2021-05-05 2024-01-16 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cancer
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
WO2022261310A1 (fr) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Inhibiteurs de mcl-1 en combinaison avec des conjugués anti-corps-médicament
CN117651554A (zh) 2021-06-11 2024-03-05 吉利德科学公司 Mcl-1抑制剂与抗癌剂的组合
WO2022271659A1 (fr) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Composés modulant les diacylglycérol kinases
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
WO2022271684A1 (fr) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Composés modulant les diacylglycérol kinases
JP7686086B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
AU2022375782A1 (en) 2021-10-28 2024-05-02 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
MX2024005928A (es) 2021-11-16 2024-06-04 Janssen Pharmaceutica Nv 2-amino-but-3-enamidas macrociclicas como inhibidores de mcl-1.
US20230220106A1 (en) 2021-12-08 2023-07-13 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
WO2023107956A1 (fr) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Protéines se liant à nkg2d, cd16 et 5t4
EP4452414A2 (fr) 2021-12-22 2024-10-30 Gilead Sciences, Inc. Agents de dégradation de doigt de zinc de la famille ikaros et utilisations associées
CA3237577A1 (fr) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Agents de degradation des doigts de zinc de la famille ikaros et leurs utilisations
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2023178181A1 (fr) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Agents de dégradation des doigts de zinc de la famille ikaros et leurs utilisations
JP2025509662A (ja) 2022-03-24 2025-04-11 ギリアード サイエンシーズ， インコーポレイテッド Ｔｒｏｐ－２発現がんを治療するための併用療法
CA3254998A1 (fr) * 2022-04-05 2023-10-12 Amgen Inc Formes de sel et solvates d'antagonistes de mci-1
JP2025511331A (ja) * 2022-04-05 2025-04-15 アムジエン・インコーポレーテツド Ｍｃｉ－１アンタゴニストの非晶質及び結晶性形態
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
WO2023205719A1 (fr) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Composés modulateurs de kras g12d
WO2023225359A1 (fr) 2022-05-20 2023-11-23 Novartis Ag Conjugués anticorps-médicament de composés anti-cancéreux et procédés d'utilisation
CA3260083A1 (fr) 2022-07-01 2024-01-04 Gilead Sciences Inc Composés cd73
WO2024064668A1 (fr) 2022-09-21 2024-03-28 Gilead Sciences, Inc. POLYTHÉRAPIE ANTICANCÉREUSE PAR RAYONNEMENT IONISANT FOCAL ET PERTURBATION CD47/SIRPα
US20240254118A1 (en) 2022-12-22 2024-08-01 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
AU2024252725A1 (en) 2023-04-11 2025-11-06 Gilead Sciences, Inc. Kras modulating compounds
CN121079300A (zh) 2023-04-21 2025-12-05 吉利德科学公司 Prmt5抑制剂及其用途
WO2025006720A1 (fr) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Composés modulateurs de kras
WO2025024811A1 (fr) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Inhibiteurs de parp7
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
EP4516807A1 (fr) 2023-08-28 2025-03-05 Consorcio Centro de Investigación Biomédica en Red Compositions destinées à être utilisées dans un procédé de fourniture d'une greffe améliorée de cellules souches hématopoïétiques
WO2025054347A1 (fr) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Composés de modulation de kras g12d
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025096589A1 (fr) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Inhibiteurs de prmt5 et leurs utilisations
WO2025111450A1 (fr) 2023-11-22 2025-05-30 Les Laboratoires Servier Conjugués anticorps anti-cd74-médicament et leurs procédés d'utilisation
WO2025111431A1 (fr) 2023-11-22 2025-05-30 Les Laboratoires Servier Conjugués anticorps-médicament anti-cd7 et leurs procédés d'utilisation
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
WO2025137640A1 (fr) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Inhibiteurs azaspiro de wrn
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6042820A (en) 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
US6472375B1 (en) 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
ES2400371T3 (es) * 2005-07-07 2013-04-09 Abbott Laboratories Promotores de la apoptosis
JP5496877B2 (ja) 2007-04-16 2014-05-21 アッヴィ・インコーポレイテッド ７−置換インドールＭｃｌ−１阻害薬
WO2009016132A1 (fr) * 2007-07-27 2009-02-05 Janssen Pharmaceutica Nv Pyrrolopyrimidines
US8975286B2 (en) * 2009-08-20 2015-03-10 Merck Sharp & Dohme Corp. Ether benzotriazole derivatives
MX2012004064A (es) * 2009-10-08 2012-06-08 Sanford Burnham Med Res Inst Derivados apogosipolona como agentes antineoplasicos.
CA2787784A1 (fr) * 2010-01-29 2011-08-04 Dana-Farber Cancer Institute, Inc. Petites molecules pour la modulation de mcl-1 et procedes de modulation de la mort cellulaire, la division cellulaire, la differenciation cellulaire et procedes de traitement de troubles
US9486422B2 (en) 2011-10-06 2016-11-08 The Regents Of The University Of Michigan Small molecule inhibitors of Mcl-1 and the uses of thereof
ES2657649T3 (es) * 2012-03-29 2018-03-06 The Regents Of The University Of Michigan Inhibidores de Mcl-1 de molécula pequeña y sus usos
JO3474B1 (ar) 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
US11306107B2 (en) 2016-02-25 2022-04-19 Amgen Inc. Compounds that inhibit MCL-1 protein

Also Published As

Publication number Publication date
CL2017000469A1 (es) 2017-11-03
ME03313B (fr) 2019-10-20
AR101729A1 (es) 2017-01-11
CR20170116A (es) 2017-04-28
TWI676628B (zh) 2019-11-11
TR201901312T4 (tr) 2019-02-21
EP3424931A2 (fr) 2019-01-09
US20190016736A1 (en) 2019-01-17
LT3186259T (lt) 2019-02-25
EP3424931B1 (fr) 2020-02-12
US20200062780A1 (en) 2020-02-27
CA2959615C (fr) 2023-01-17
US10836779B2 (en) 2020-11-17
MX2017002656A (es) 2017-10-12
TW201625645A (zh) 2016-07-16
IL250843A0 (en) 2017-04-30
RS58276B1 (sr) 2019-03-29
CN107001387A (zh) 2017-08-01
MX379155B (es) 2025-03-11
TN2017000067A1 (en) 2018-07-04
US20210040120A1 (en) 2021-02-11
AP2017009827A0 (en) 2017-03-31
HRP20190053T1 (hr) 2019-02-22
SMT201900048T1 (it) 2019-02-28
SG11201701525WA (en) 2017-03-30
EP3186259A1 (fr) 2017-07-05
US20160068545A1 (en) 2016-03-10
CA2959615A1 (fr) 2016-03-03
US20230271981A1 (en) 2023-08-31
UA118233C2 (uk) 2018-12-10
US20170088560A1 (en) 2017-03-30
AU2015308735B2 (en) 2019-03-14
BR112017004209A2 (pt) 2018-07-31
MY176235A (en) 2020-07-24
JP2017525730A (ja) 2017-09-07
CO2017002998A2 (es) 2017-07-19
EP3424931A3 (fr) 2019-02-20
ZA201802865B (en) 2022-05-25
BR112017004209B1 (pt) 2022-08-09
JO3474B1 (ar) 2020-07-05
DK3186259T3 (en) 2019-02-25
MA40111A1 (fr) 2018-06-29
UY36285A (es) 2016-04-01
KR20170043661A (ko) 2017-04-21
HUE041806T2 (hu) 2019-05-28
KR102466351B1 (ko) 2022-11-10
CN107001387B (zh) 2019-03-05
AU2015308735A1 (en) 2017-03-23
US9562061B2 (en) 2017-02-07
PH12017500367A1 (en) 2017-07-10
NZ729768A (en) 2021-06-25
EA201790492A1 (ru) 2017-07-31
ZA201701763B (en) 2018-08-29
PE20170892A1 (es) 2017-07-12
US20190023720A1 (en) 2019-01-24
PH12017500367B1 (en) 2017-07-10
EA031223B1 (ru) 2018-12-28
ES2777478T3 (es) 2020-08-05
US10494381B2 (en) 2019-12-03
PL3186259T3 (pl) 2019-04-30
US10100063B2 (en) 2018-10-16
IL257942B (en) 2020-05-31
SI3186259T1 (sl) 2019-03-29
US11685747B2 (en) 2023-06-27
IL257942A (en) 2018-05-31
US12024529B2 (en) 2024-07-02
ES2706309T3 (es) 2019-03-28
IL250843B (en) 2018-03-29
JP6502479B2 (ja) 2019-04-17
PT3186259T (pt) 2019-02-06
CY1121195T1 (el) 2020-05-29
US11001598B2 (en) 2021-05-11
EP3186259B1 (fr) 2018-12-19
WO2016033486A1 (fr) 2016-03-03

Similar Documents

Publication Publication Date Title
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MA39783B1 (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA39898B1 (fr) Composés 4-amino-imidazoquinoline
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
MA34903B1 (fr) Derives de type azaindazole ou diazaindazole utilises comme medicaments
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA44674A (fr) Inhibiteurs de bromodomaine
MA40768A (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
EA201690077A1 (ru) Терапевтически активные производные эстратриен-тиазола
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
MA44079B1 (fr) Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine
MA39253A1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA42769B1 (fr) Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1
MA41174B1 (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
MA39926B1 (fr) Dérivés de dihétérocycle liés à cycloalkyle
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA33979B1 (fr) Piperazines en tant qu'agents antipaludiques